NCT07859865 · ACTIVE NOT RECRUITING

Mindfulness-based Movement Therapy for Persons With Dementia and Family Caregivers

This study tests whether a program called CARE-MOVE is workable and acceptable for people caring for someone with dementia. It combines mindfulness-based dance and movement sessions, education, and a support group. Researchers also look at early signs of changes in stress, well-being, and the caregiving relationship. It is a behavioral study with no phase, so it is an early look, not proof it works.

You may qualify if

  • Age 18 years or older
  • Informal care partner of a person living with dementia and has known the care recipient for at least 1 year
  • Care recipient has a diagnosis of Alzheimer's disease, frontotemporal dementia, vascular dementia, Lewy body disease, or mixed dementia
  • English speaking
  • Normal or corrected-to-normal visual acuity and normal color vision, based on self-report
  • Adequate hearing acuity, based on self-report
  • Able to use a tablet or computer, email, and complete online surveys independently or with readily available assistance
  • Has internet access with Wi-Fi at the location where CARE-MOVE sessions will be attended
  • Able to safely participate in a light- to moderate-intensity movement-based intervention
  • Willing to participate in the CARE-MOVE intervention

You're excluded if

  • Health condition that may contraindicate participation in light- to moderate-intensity movement, such as an unstable cardiac condition, previous myocardial infarction, angina, or chronic obstructive pulmonary disease, unless medical clearance is provided by a physician
  • Surgery within the previous 1 year
  • New pain medication or psychotropic medication, or a change in pain or psychotropic medication, within the previous 60 days

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-10-08

View full record on ClinicalTrials.gov

All APOE4 clinical trials